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Introduction {#mbt213270-sec-0001}
============

Since at least December 2015, when an overwhelming majority of nations worldwide agreed on signing the Paris Climate Agreement, scientific theories of climate change attributing the increasing man‐made release of CO~2~ a dominating role started to drive political and economic decision‐making (Philip, [2018](#mbt213270-bib-0111){ref-type="ref"}). Further supported by the inherent fear of diminishing fossil resources, oil‐based chemical industries worldwide began to develop future scenarios for ensuring the current product portfolios, aiming for zero‐CO~2~ emission strategies. At best, future processes should not only prevent non‐necessary CO~2~ emissions, preferred production technologies should even incorporate CO~2~ (Bengelsdorf and Dürre, [2017](#mbt213270-bib-0008){ref-type="ref"}), thereby contributing to the climate goals and preventing costly payments for CO~2~ certificates.

One strategy to prevent CO~2~ emissions is the implementation of the so‐called circular economy, that is the use of sugar contents in lignocellulosic feedstocks such as agri‐residues, agri‐processing by‐products and energy crops for the microbial production of value‐added products such as biofuels or fine chemicals (Liguori and Faraco, [2016](#mbt213270-bib-0086){ref-type="ref"}). Expectations formulated in the US Energy Independence and Security Act (2007) specified 35 billion gallons of ethanol equivalents to be used in 2022 as a strategic goal. However, the technically and economically successful implementation of such processes has revealed to be very challenging, still requiring progress. Handling and use of the lignin fraction including energy management is one of the challenges.

Biomass gasification either conventional (Griffin and Schultz, [2012](#mbt213270-bib-0052){ref-type="ref"}) or via fast pyrolysis (Pfitzer *et al*., [2016](#mbt213270-bib-0110){ref-type="ref"}; Arnold *et al*., [2017](#mbt213270-bib-0006){ref-type="ref"}) is very well suited to use lignin‐containing sources such as wood or even municipal wastes for the production of CO and H~2~ containing gases, further called 'syngas' for simplification (LanzaTech, [2017](#mbt213270-bib-0082){ref-type="ref"}). Such compositions vary between 30--60% CO, 25--30% H~2~, 0--5% CH~4~, 5--1 5% CO~2~, may contain other impurities such as H~2~S, NH~3~ and depend heavily on the source. A key transformation is the so‐called water/gas‐shift (WGS) reaction that converts CO and H~2~O into CO~2~ and H~2~ under high pressure and high temperatures (\> 600°C) thus representing a source of H~2~ production. Besides for heat and power supply, syngas is applied in Fischer--Tropsch (FT) synthesis for the production of naphtha‐like mixtures, diesel, methanol or even ethanol. However, such processes are not only energy‐intensive (20--300 bar, 200--350°C), and they also require the removal of impurities like tars to protect the Rh catalysts. Furthermore, optimum FT conversions are only achieved if the preferred ratio H~2~ to CO of \> 2 is installed (Abubackar *et al*., [2011](#mbt213270-bib-0002){ref-type="ref"}; Griffin and Schultz, [2012](#mbt213270-bib-0052){ref-type="ref"}).

Interesting enough, nature provides a whole bunch of fermentative microbes that may grow on H~2~, CO and CO~2~ compositions via hydrogenesis, methanogenesis or acetogenesis (Latif *et al*., [2014](#mbt213270-bib-0083){ref-type="ref"}; Diender *et al*., [2015](#mbt213270-bib-0037){ref-type="ref"}). The latter are particularly promising for industrial application as they make use of the reductive acetyl‐CoA pathway (Dürre, [2016](#mbt213270-bib-0038){ref-type="ref"}). In a nutshell, CO and H~2~ serve as electron donors enabling the growth on CO~2~ and H~2~, or CO, or CO and H~2~ to produce mixtures of acetate, ethanol, 2,3 butanediol, etc. (Daniell *et al*., [2012](#mbt213270-bib-0031){ref-type="ref"}). Accordingly, not only syngas, but also other off‐gas compositions, for example from coke oven plants and steel industry, may provide valuable electron sources for the microbes. Thereby, the CO dehydrogenase (CODH) is the enabling enzyme and the biological equivalent to the harsh technical approach, however, working under moderate, anaerobic conditions. Furthermore, feasible H~2~/CO ratios are much more flexible than in Fischer--Tropsch (FT) processes (Munasinghe and Khanal, [2010](#mbt213270-bib-0105){ref-type="ref"}), albeit cellular performance might suffer from gas impurities such as sulfur dioxide or hydrogen sulfide. Nevertheless, such processes offer the potential to be economically superior to conventional FT approaches (Griffin and Schultz, [2012](#mbt213270-bib-0052){ref-type="ref"}). Nevertheless, some inherent drawbacks still hamper the success of acetogenic production processes. Engineering challenges are mirrored by the poor water solubilities and low Henry constants of CO and H~2~ which are about 30 and 1.6 mg l^−1^ (of pure gases), and 27.1 and 1.6 mg bar^−1^ respectively.

Aside from the anaerobic, acetogenic bacteria, the aerobic carboxydotrophic bacteria are promising candidates for microbial production of value‐added products from gases. These organisms are able to grow chemolithoautotrophically on CO or syngas by use of the reductive pentose phosphate pathway for anabolism and O~2~ as final electron acceptor in energy metabolism. Aerobic CO oxidation is more exotherm and allows higher ATP generation than anaerobic fermentation with CO, and therefore, the production of complex and more ATP‐intensive products should be feasible. However, molecular toolboxes for carboxydotrophic bacteria are missing, and thus, strain engineering is also still challenging.

This review not only provides biological and technical fundamentals for using acetogenic or aerobic, carboxydotrophic bacteria in gas fermentation, it also outlines the industrial point of view integrating such bioprocesses into both existing infrastructure and existing value‐added chains (VACs). Thereof, conclusions will be drawn to make zero‐CO~2~ initiatives an environmental and economic success.

The *status quo* in chemical industry {#mbt213270-sec-0002}
=====================================

The production landscape in chemical industry is often organized in value‐added chains (VACs), each leading from basic raw materials to molecules of interest via specific, often multifunctional intermediates. Currently, most VACs are based on fossil raw materials deploying homogeneous and heterogeneous chemical catalysis as major synthesis technologies. However, driven by competitiveness and the mindset of zero‐CO~2~ emission processes, the use of alternative raw materials, such as renewable raw materials (RRM), is gaining importance.

Nevertheless, such processes necessarily need to offer competitive products, produced via efficient approaches delivering material with at least the same quality and performance as produced from fossil resources. Irrespective of the raw material used and the chemical or biochemical conversions applied, the following constraints need to be fulfilled for each industrial process:

New processes to produce existing products (drop‐in) need to show the potential to reach the efficiency and economic performance of mature traditional production routes;Product and process specifications need to consider the variability in raw material and the consequences of biosynthesis;Methods, techniques and equipment to economically handle large amounts of aqueous systems and purify molecules of interest in an aqueous environment are indispensable;In the long run, and taking into account both, economic reality and depreciation of existing assets, current VACs might need to be altered to take full advantage of bio‐based processes which might lead to new molecules.

On the other hand, gaseous substrates such as H~2~, CO and CO~2~ offer general benefits such as global availability, large capacities, no interference with food or feed (based on gas generation from fossil resources or wastes), predictable pricing through well‐known mechanisms, full metabolic usability, potentially less impurities derived from non‐reactive carbon, good storability, reduced risk of infection, access from waste streams and enabler for circular economy considerations.

Products of interest {#mbt213270-sec-0003}
====================

Driven by the inherent potential of gas fermentation, chemical industry should have a key interest to evaluate gaseous substrates for production purposes for intermediates as well as for performance molecules. Examples of the first are compounds such as 3‐hydroxypropionic acid, succinic acid, itaconic acid, 1,4‐butanediol, isobutene, 1‐octanol, methyl methacrylate (MMA), butadiene, fatty acids, amino acids. Examples of the second are highly functionalized short‐ and medium‐chain molecules, active pharma ingredients, vitamins, industrial enzymes, proteins, etc. It is particularly the first group that feels the strongest market pressure of success which is mirrored by the competition with traditional, fossil‐based production technologies, the high cost pressure and strict specifications given by chemical VACs and applications. On the other side, physicochemical properties of the compounds are often well known which offers a broad range of feasible downstream processing (DSP) unit operations, including non‐aqueous media in medium‐ to large‐size production volumes.

To be successful, intermediates and performance molecules need to fulfil different criteria which mirror the individual production and market scenarios. Given the typically large market volumes of intermediates, also called commodities, of \> 100.000 tons per year, maximum product concentrations (\>100 g kg^−1^), production rates (\> 4 g kg^−1^ h^−1^), conversion and downstream processing yields, and highest product purity are crucial properties. On the other hand, high‐process flexibility and product innovation levels are characteristic for performance molecules (see Fig. [1](#mbt213270-fig-0001){ref-type="fig"}). As a consequence, gaseous substrates are particularly attractive for the production of commodities and are in the focus of current studies.

![Crucial properties of success are given for intermediates of VACs (indicated as small molecules) and performance molecules (indicated as industrial enzymes). The ranking from 0 to 10 represents a qualitative measure.](MBT2-11-606-g001){#mbt213270-fig-0001}

Economic constraints of attractive gaseous substrates {#mbt213270-sec-0004}
=====================================================

The economic success of a gas fermentation‐based process will depend on several factors. First and foremost, the nature of the gaseous substrate is key. Gas mixtures of CO, CO~2~ and H~2~ are favourable due the inherent energy content of CO and H~2~. Off‐gases containing exclusively CO~2~ (\> 95%) are less attractive, however, available in large amounts from power plants or large‐scale fermentations (e.g. bioethanol production). Unlike syngas, CO~2~‐rich waste streams are inert and CO~2~ activation requires reductive energy. Therefore, economic viability is crucially dependent on the availability of cheap and renewable electricity which has to be considered as the other feedstock besides CO~2~.

Hydrogen is a versatile energy transport molecule that can be stored using existing technologies (compression, hydrogen--gas grids). Currently, hydrogen formation by the alkaline technology or by the more preferable Proton‐Exchange‐Membrane (PEM) technology is still not cost competitive to the alternative Steam‐Methane‐Reformation (SMR) process that uses natural gas (methane). The latter liberates CO~2~, still, in some cases, the stoichiometry of the overall production process allows for a net fixation of CO~2~. In these cases, SMR can serve as a bridging technology towards a fully renewable process that is based on the flexible PEM technology. PEM hydrolyzers are costly, but prices are expected to fall by more than 30% within the next years (Bertuccioli *et al*., [2014](#mbt213270-bib-0015){ref-type="ref"} ). Considering that electricity prices dominate hydrogen--feedstock costs, product formation from CO~2~ will be most attractive during periods of surplus wind‐ and solar energy. Coupling of the energy providing industries with chemical industries (sector coupling) will be of increasing importance. However, existing regulatory frameworks have to be considered which might hamper cross‐industry synergies.

Molecular oxygen is the other product of the water splitting reaction and will be available in high purities and in large amounts, thus credits from O~2~ production can lower the hydrogen production costs. The often asynchronous availability of the three gases CO~2~, H~2~ and O~2~ asks for smart gas storage systems, but compressing gases is an established, however, energy‐demanding technique. Again, availability of cheap energy enters centre stage.

The common notion about CO~2~ is a valueless waste stream instead of a valuable feedstock. The revenues from the European Emissions Trading System (ETS certificates, about 7 €/ton) currently underpin this notion. They are too low to have a positive impact on business models that aim for CO~2~ upgrading (Pérez‐Fortes *et al*., [2016](#mbt213270-bib-0109){ref-type="ref"}). However, depending on its purity, CO~2~ already has some markets mainly in food industries (beverages, green houses), thereby generating revenues with comparably little need of costly upfront investments (CAPEX, e.g., for gas stripping and compression technologies). CO~2~ finds further applications as co‐polymer in chemical synthesis, as shielding gas, extinguishing agent and as coolant. Existing CO~2~ markets compete for the feedstock with the novel VACs to be established. However, CO~2~ availability at point sources (steel mills, power stations, large‐scale biological fermentations) outnumbers the current demand by orders of magnitude (Mikkelsen *et al*., [2010](#mbt213270-bib-0099){ref-type="ref"}). Accordingly, low CO~2~ feedstock prices will stay rather stable in the foreseeable future. For economic reasons, point sources of CO~2~ should be located at sites where renewable energy is available in sufficient amounts, for example Iceland (geothermal energy), Morocco (solar) or Norway (wind). Liquification of CO~2~ is an established technology, and long‐distance transport is economically viable for other gases (e.g. LNG, liquified natural gas). Unlike syngas, CO~2~ is available from the atmosphere in almost unlimited quantities. Average annual anthropogenic CO~2~ emissions are in the range of 35 ‐ 40 Gt, and CO~2~ emissions from fossil fuels and industry are expected to grow (Le Quéré *et al*., [2017](#mbt213270-bib-0084){ref-type="ref"}). Consequently, direct air‐capture of CO~2~ in combination with gas fermentation at preferred sites becomes an interesting future option to enable economically viable production processes at currently unrecognized places. First pilot and commercial processes for direct air‐capture have been implemented but lack economic competitiveness at present (Climeworks, Skytree). With regard to syngas, gas fermentation facilities will have to be located next to the syngas‐emitting point source, and the first pilot‐ and demonstration‐scale processes are implemented (Lanzatech, [2017](#mbt213270-bib-0082){ref-type="ref"}).

The industrial wish list of microbial properties {#mbt213270-sec-0005}
================================================

Any microbial strain used in industrial applications needs to meet basic expectations. Properties such as high product tolerance, robustness with respect to harsh production conditions, genetic stability and high substrate uptake and conversion rates are highly appreciated aside from the expected high conversion yields. Regarding gas fermentations, the wish list can even be extended: the gaseous substrate might contain oxygen along with other trace toxins (e.g. sulfide) finally accumulating in the nutrient broth. Accordingly, oxygen tolerance is desirable, although somewhat contradicting with the native endowments of anaerobic acetogenic bacteria that are often applied. Similarly, microbes should tolerate elevated substrate levels (CO~2~, H~2~, CO), which are often mandatory in technical processes. Also, pH drops should be accepted because acid production typically coincides with the production of the product of choice.

Fermentative metabolism of CO, H~2~ and CO~2~ containing gases {#mbt213270-sec-0006}
==============================================================

Anaerobic acetogenic bacteria use the so‐called Wood--Ljungdahl pathway for fixation of CO~2~ or CO (Bengelsdorf *et al*., [2018](#mbt213270-bib-0013){ref-type="ref"}). This pathway consists of two parts: the methyl and the carbonyl branch. In the former, a molecule of CO~2~ is reduced to formate (in case of CO as a carbon source, this is first oxidized to CO~2~) (Fig. [2](#mbt213270-fig-0002){ref-type="fig"}). Formate is coupled to the coenzyme tetrahydrofolate, thereby hydrolysing one ATP into ADP and inorganic phosphate. Then, the C~1~ unit is successively reduced to methyl‐tetrahydrofolate, and the methyl group is transferred to an iron--sulfur--corrinoid protein. In the carbonyl branch, a molecule of CO~2~ is reduced to CO, using reduced ferredoxin, by the enzyme acetyl‐CoA synthase/CO dehydrogenase, which then also combines the methyl group of the iron--sulfur--corrinoid protein, a CoA moiety and the carbonyl group into acetyl‐CoA. This intermediate is further metabolized into acetate, yielding one ATP in the acetate kinase reaction. Thus, no substrate level‐phosphorylated ATP is left for growth and biosynthetic reactions. Acetogens obtain additional energy from ion gradients, either generated by the so‐called Rnf complex (a reduced ferredoxin: NAD^+^ oxidoreductase, producing thereby either a proton or a Na^+^ gradient) or the Ech complex, which oxidizes reduced ferredoxin, reduces protons, thereby producing hydrogen and translocates protons across the cytoplasmic membrane (Schuchmann and Müller, [2014](#mbt213270-bib-0127){ref-type="ref"}). Acetogens that produce ethanol in addition to acetate do so using an aldehyde: ferredoxin oxidoreductase, which converts acetate and reduced ferredoxin to acetaldehyde that, in a further enzymatic reaction, is reduced to ethanol. This way, the bacteria are still able to generate ATP from acetate formation. Reducing equivalents are usually produced by bifurcating hydrogenases that oxidize two H~2~ and reduce both, ferredoxin and NAD^+^.

![Syngas sources, anaerobic and aerobic syngas fermentation, model organisms involved, and natural and recombinant products.](MBT2-11-606-g002){#mbt213270-fig-0002}

Numerous acetogens are currently known (Table [1](#mbt213270-tbl-0001){ref-type="table"}). However, only few serve as model organisms and industrial workhorses, that is *Acetobacterium woodii*,*Clostridium ljungdahlii*,*Moorella thermoacetica* and *Clostridium autoethanogenum*. Although the current scientific and industrial interest mostly focuses on the autotrophic features, it must be mentioned that all acetogens known are also able to use a number of heterotrophic substrates. *A. woodii* was isolated in 1977, when the very first described autotrophic acetogen, that is *C. aceticum* was still considered to be lost (Balch *et al*., [1977](#mbt213270-bib-0007){ref-type="ref"}). *C. aceticum* was only rediscovered in 1980 and later completely sequenced (Braun *et al*., [1981](#mbt213270-bib-0019){ref-type="ref"}; Poehlein *et al*., [2015a](#mbt213270-bib-0117){ref-type="ref"},[b](#mbt213270-bib-0118){ref-type="ref"},[c](#mbt213270-bib-0119){ref-type="ref"}). *A. woodii* does not use CO as a substrate, but is very efficient in fermenting CO~2~/H~2~ gas mixtures. It is now considered as the model acetogen for sodium bioenergetics. Energy conservation is based on a Rnf complex that exports Na^+^ ions and a sodium‐dependent ATPase that imports Na^+^ ions for ATP generation (Müller *et al*., [2001](#mbt213270-bib-0104){ref-type="ref"}; Biegel and Müller, [2010](#mbt213270-bib-0016){ref-type="ref"}; Hess *et al*., [2013](#mbt213270-bib-0058){ref-type="ref"}). The organism is genetically accessible since more than 20 years (Strätz *et al*., [1994](#mbt213270-bib-0136){ref-type="ref"}), the complete genome sequence is known (Poehlein *et al*., [2012](#mbt213270-bib-0115){ref-type="ref"}), *A. woodii* can be grown in bioreactors with continuous gas supply, and recombinant strains for non‐natural product formation (acetone) have been constructed and tested (Straub *et al*., [2014](#mbt213270-bib-0137){ref-type="ref"}; Hoffmeister *et al*., [2016](#mbt213270-bib-0059){ref-type="ref"}; Kantzow and Weuster‐Botz, [2016](#mbt213270-bib-0069){ref-type="ref"}).

###### 

Acetogens and their major characteristics

  Organism                                                                                 Substrate                           Products/Methanol utilization (yes or no)   Optimal growth temperature \[°C\]            Optimal pH                                    Doubling time (autotrophic) \[h\]   Genome accession number   References
  ---------------------------------------------------------------------------------------- ----------------------------------- ------------------------------------------- -------------------------------------------- --------------------------------------------- ----------------------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Acetitomaculum ruminis* DSM 5522                                                        H~2~ + CO~2~, CO                    Acetate/no                                  37--42                                       6.8                                           H~2~ + CO~2~: 2.1                   FOJY00000000              (Greening and Leedle, [1989](#mbt213270-bib-0051){ref-type="ref"})
  *Acetoanaerobium noterae* ATCC 35199                                                     H~2~ + CO~2~                        Acetate/no                                  37                                           7.6--7.8                                      H~2~ + CO~2~: 27                    FUYN00000000              (Sleat *et al*., [1985](#mbt213270-bib-0134){ref-type="ref"})
  *Acetobacterium bakii* DSM 8239                                                          H~2~ + CO~2~, CO                    Acetate/yes                                 20                                           6.5                                                                               LGYO01000000              (Kotsyurbenko *et al*., [1995](#mbt213270-bib-0077){ref-type="ref"} Hwang *et al*., [2015](#mbt213270-bib-0064){ref-type="ref"})
  *Acetobacterium carbinolicum* DSM 2925                                                   H~2~ + CO~2~                        Acetate/yes                                 27                                           7.0--7.2                                                                                                    (Eichler and Schink, [1984](#mbt213270-bib-0041){ref-type="ref"}; Schuppert and Schink, [1990](#mbt213270-bib-0129){ref-type="ref"})
  *Acetobacterium dehalogenans* DSM 11527                                                  H~2~ + CO~2~, CO                    Acetate/yes                                 25                                           7.3--7.7                                                                          AXAC01000000              (Traunecker *et al*., [1991](#mbt213270-bib-0141){ref-type="ref"})
  *Acetobacterium fimetarium* DSM 8238                                                     H~2~ + CO~2~, CO                    Acetate/no                                  30                                           7.5                                                                                                         (Kotsyurbenko *et al*., [1995](#mbt213270-bib-0077){ref-type="ref"})
  *Acetobacterium malicum* DSM 4132                                                        H~2~ + CO~2~                        Acetate/no                                  30                                           7.5--8.0                                                                                                    (Tanaka and Pfennig, [1988](#mbt213270-bib-0139){ref-type="ref"})
  *Acetobacterium paludosum* DSM 8237                                                      H~2~ + CO~2~, CO                    Acetate/yes                                 20                                           7.0                                                                                                         Kotsyurbenko *et al*., [1995](#mbt213270-bib-0077){ref-type="ref"})
  *Acetobacterium tundrae* DSM 9173                                                        H~2~ + CO~2~, CO                    Acetate/yes                                 20                                           7.0                                                                                                         (Simankova *et al*., [2000](#mbt213270-bib-0132){ref-type="ref"})
  *Acetobacterium wieringae* DSM 1911                                                      H~2~ + CO~2~                        Acetate/no                                  30                                           7.6                                                                               LKEU00000000              (Braun and Gottschalk, [1982](#mbt213270-bib-0018){ref-type="ref"} Poehlein *et al*., [2016](#mbt213270-bib-0120){ref-type="ref"})
  *Acetobacterium woodii* DSM 1030                                                         H~2~ + CO~2~                        Acetate/yes                                 30                                           7.6                                                                               CP002987                  (Balch *et al*., [1977](#mbt213270-bib-0007){ref-type="ref"}; Bache and Pfennig, [1981](#mbt213270-bib-0501){ref-type="ref"}; Genthner and Bryant, [1982](#mbt213270-bib-0045){ref-type="ref"}; Schink and Stieb, [1983](#mbt213270-bib-0126){ref-type="ref"}; Poehlein *et al*., [2012](#mbt213270-bib-0115){ref-type="ref"})
  *Acetohalobium arabaticum* DSM 5501                                                      H~2~ + CO~2~, CO                    Acetate/no                                  38--40                                       7.6--8.0                                                                          CP002105                  (Zhilina and Zavarzin, [1990](#mbt213270-bib-0158){ref-type="ref"} Sikorski *et al*., [2010](#mbt213270-bib-0131){ref-type="ref"})
  *Acetonema longum* DSM 6540                                                              H~2~ + CO~2~                        Acetate, butyrate/n.r.                      30--33                                       7.8                                                                               AFGF01000000              (Kane and Breznak, [1991](#mbt213270-bib-0066){ref-type="ref"} Chen *et al*., [2011](#mbt213270-bib-0026){ref-type="ref"})
  *Alkalibaculum bacchi* DSM 22112                                                         H~2~ + CO~2~, CO                    Acetate, CO~2~, ethanol/yes                 37                                           8.0--8.5                                                                                                    (Allen *et al*., [2010](#mbt213270-bib-0003){ref-type="ref"})
  *Blautia coccoides* GA‐1[a](#mbt213270-note-0003){ref-type="fn"} n.d.                    H~2~ + CO~2~                        Acetate/n.r.                                37[b](#mbt213270-note-0004){ref-type="fn"}   7.0[c](#mbt213270-note-0005){ref-type="fn"}                                                                 (Kaneuchi *et al*., [1976](#mbt213270-bib-0068){ref-type="ref"}; Liu *et al*., [2008](#mbt213270-bib-0088){ref-type="ref"}, [2015](#mbt213270-bib-0089){ref-type="ref"})
  *Blautia hydrogenotrophica* DSM 10507                                                    H~2~ + CO~2~                        Acetate/n.r.                                35--37                                       6.6                                                                               CYXL01000000              (Bernalier *et al*., [1996](#mbt213270-bib-0014){ref-type="ref"}; Liu *et al*., [2008](#mbt213270-bib-0088){ref-type="ref"})
  *Blautia producta* U‐1[a](#mbt213270-note-0003){ref-type="fn"} DSM 3507                  H~2~ + CO~2~, CO                    Acetate/no                                  37                                                                                         CO: 1.5‐3                           AUUC00000000              (Lorowitz and Bryant, [1984](#mbt213270-bib-0090){ref-type="ref"}; Geerligs *et al*., [1987](#mbt213270-bib-0044){ref-type="ref"}; Liu *et al*., [2008](#mbt213270-bib-0088){ref-type="ref"})
  *Blautia schinkii* DSM 10518                                                             H~2~ + CO~2~                        Acetate/no                                  39                                           6.5--7.0                                                                          JNKJ01000000              (Rieu‐Lesme *et al*., [1996](#mbt213270-bib-0123){ref-type="ref"}; Liu *et al*., [2008](#mbt213270-bib-0088){ref-type="ref"})
  *'Butyribacterium methylotrophicum'* [c](#mbt213270-note-0005){ref-type="fn"} DSM 3468   H~2~ + CO~2~, CO (after adaption)   Acetate, ethanol, butyrate, butanol/yes     37--40                                       7.5                                           CO: 13.9                            MIMZ00000000              (Zeikus *et al*., [1980](#mbt213270-bib-0157){ref-type="ref"}; Lynd *et al*., [1982](#mbt213270-bib-0092){ref-type="ref"} Bengelsdorf *et al*., [2016b](#mbt213270-bib-0012){ref-type="ref"})
  *Clostridium aceticum* DSM 1496                                                          H~2~ + CO~2~, CO                    Acetate/no                                  30                                           8.3                                           H~2~ + CO~2~: 20‐25                 CP009687‐CP009688         (Wieringa, [1936](#mbt213270-bib-0151){ref-type="ref"}; Lux and Drake, [1992](#mbt213270-bib-0091){ref-type="ref"}; Braun *et al*., [1981](#mbt213270-bib-0019){ref-type="ref"} Poehlein *et al*., [2015c](#mbt213270-bib-0119){ref-type="ref"})
  *'Clostridium autoethanogenum'* [c](#mbt213270-note-0005){ref-type="fn"} DSM 10061       H~2~ + CO~2~, CO                    2,3‐butanediol, acetate, ethanol/no         37                                           5.8--6.0                                      CO: 4                               CP006763                  (Abrini *et al*., [1994](#mbt213270-bib-0001){ref-type="ref"}; Köpke *et al*., [2011](#mbt213270-bib-0075){ref-type="ref"} Brown *et al*., [2014](#mbt213270-bib-0022){ref-type="ref"})
  *Clostridium carboxidivorans* DSM 15243                                                  H~2~ + CO~2~, CO                    Acetate, ethanol, butyrate, butanol/no      38                                           5.0--7.0                                      CO: 6.3, H~2~ + CO~2~: 8.3          CP011803‐CP011804         (Liou *et al*., [2005](#mbt213270-bib-0087){ref-type="ref"})
  *'Clostridium coskatii'* [c](#mbt213270-note-0005){ref-type="fn"} ATCC PTA‐10522         H~2~ + CO~2~, CO                    Acetate, ethanol/no                         37                                           5.8--6.5                                                                          LROR00000000              (Zahn and Saxena, [2012](#mbt213270-bib-0155){ref-type="ref"} Bengelsdorf *et al*., [2016a](#mbt213270-bib-0011){ref-type="ref"};
  *Clostridioides difficile* 630[a](#mbt213270-note-0003){ref-type="fn"} DSM 27543         H~2~ + CO~2~                        Acetate/n.r.                                37[b](#mbt213270-note-0004){ref-type="fn"}   5.9[b](#mbt213270-note-0004){ref-type="fn"}                                       CP010905                  Köpke *et al*., [2013](#mbt213270-bib-0076){ref-type="ref"} Riedel *et al*., [2015](#mbt213270-bib-0122){ref-type="ref"})
  *Clostridium drakei* DSM 12750                                                           H~2~ + CO~2~, CO                    Acetate, ethanol, butyrate/no               30--37                                       5.4--7.5                                      CO: 8.3, H~2~ + CO~2~: 5.0          JIBU02000000              (Küsel *et al*., [2000](#mbt213270-bib-0080){ref-type="ref"}; Liou *et al*., [2005](#mbt213270-bib-0087){ref-type="ref"}; Gößner *et al*., [2008](#mbt213270-bib-0049){ref-type="ref"}; Jeong *et al*., [2014](#mbt213270-bib-0065){ref-type="ref"})
  *Clostridium formicaceticum* DSM 92                                                      CO                                  Acetate, formate/yes                        37                                           8.1                                           CO: 10                              CP020559                  (Andreesen *et al*., [1970](#mbt213270-bib-0005){ref-type="ref"}; Lux and Drake, [1992](#mbt213270-bib-0091){ref-type="ref"} Karl *et al*., [2017](#mbt213270-bib-0071){ref-type="ref"})
  *Clostridium ljungdahlii* DSM 13528                                                      H~2~ + CO~2~, CO                    2,3‐butanediol, acetate, ethanol/no         37                                           6.0                                           CO: 3.8                             CP001666                  (Tanner *et al*., [1993](#mbt213270-bib-0140){ref-type="ref"}; Köpke *et al*., [2010](#mbt213270-bib-0074){ref-type="ref"}, [2011](#mbt213270-bib-0075){ref-type="ref"})
  *Clostridium magnum* DSM 2767                                                            H~2~ + CO~2~                        Acetate/yes                                 30--32                                       7.2                                                                               LWAE00000000              (Schink, [1984](#mbt213270-bib-0125){ref-type="ref"}; Schink, [1991](#mbt213270-bib-0506){ref-type="ref"} *;* Uhlig *et al*., [2016](#mbt213270-bib-0144){ref-type="ref"})
  *Clostridium methoxybenzovorans* DSM 12182                                               H~2~ + CO~2~                        Acetate, formate/yes                        37                                           7.4                                                                               ATXD01000000              (Mechichi *et al*., [1999](#mbt213270-bib-0096){ref-type="ref"})
  *'Clostridium ragsdalei'* [c](#mbt213270-note-0005){ref-type="fn"} DSM 15248             H~2~ + CO~2~, CO                    2,3‐butanediol, acetate, ethanol/n.r.       37                                                                                         CO: 4                               LROS00000000              (Huhnke *et al*., [2008](#mbt213270-bib-0060){ref-type="ref"}; Köpke *et al*., [2011](#mbt213270-bib-0075){ref-type="ref"} Bengelsdorf *et al*., [2016a](#mbt213270-bib-0011){ref-type="ref"})
  *Clostridium scatologenes* DSM 757                                                       H~2~ + CO~2~, CO                    Acetate, ethanol, butyrate/no               37--40                                       5.4--7.0                                      CO: 11.1, H~2~ + CO~2~: 25.0        CP009933                  (Liou *et al*., [2005](#mbt213270-bib-0087){ref-type="ref"}; Zhu *et al*., [2015](#mbt213270-bib-0161){ref-type="ref"})
  *Desulfotomaculum thermobenzoicum subsp. thermosyntrophicum* DSM 14055                   H~2~ + CO~2~                        Acetate/no                                  55                                           7.0--7.5                                                                                                    (Plugge *et al*., [2002](#mbt213270-bib-0114){ref-type="ref"})
  *Eubacterium aggregans* DSM 12183                                                        H~2~ + CO~2~                        Acetate, formate/yes                        35                                           7.2                                                                               FNRK00000000              (Mechichi *et al*., [1998](#mbt213270-bib-0095){ref-type="ref"})
  *Eubacterium limosum* DSM 20543                                                          H~2~ + CO~2~, CO                    Acetate, CO~2~/yes                          39                                           7.0--7.2                                      CO: 7, H~2~ + CO~2~: 14             CP019962                  (Eggerth, [1935](#mbt213270-bib-0040){ref-type="ref"}; Bryant *et al*., [1958](#mbt213270-bib-0023){ref-type="ref"}; Genthner *et al*., [1981](#mbt213270-bib-0046){ref-type="ref"}; Genthner and Bryant, [1982](#mbt213270-bib-0045){ref-type="ref"} Song and Cho, [2015](#mbt213270-bib-0135){ref-type="ref"})
  *Fuchsiella alkaliacetigena* DSM 24880                                                   H~2~ + CO~2~                        Acetate/no                                  40                                           8.8--9.3                                                                                                    (Zhilina *et al*., [2012](#mbt213270-bib-0159){ref-type="ref"})
  *Fuchsiella ferrireducens* DSM 26031                                                     H~2~ + CO~2~                        Acetate/no                                  30--37                                       9.8                                                                                                         (Zhilina *et al*., [2015](#mbt213270-bib-0070){ref-type="ref"})
  *Holophaga foetida* [d](#mbt213270-note-0006){ref-type="fn"} DSM 6591                    N.r.                                N.r./no                                     28--32                                       6.8--7.5                                                                          AGSB02000000              (Liesack *et al*., [1994](#mbt213270-bib-0085){ref-type="ref"} Anderson *et al*., [2012](#mbt213270-bib-0004){ref-type="ref"})
  *Marvinbryantia formatexigens* DSM 14469                                                 H~2~ + CO~2~, formate               Acetate/no                                  37[b](#mbt213270-note-0004){ref-type="fn"}   7.0[b](#mbt213270-note-0004){ref-type="fn"}                                       ACCL00000000              (Wolin *et al*., [2003](#mbt213270-bib-0152){ref-type="ref"}, [2008](#mbt213270-bib-0153){ref-type="ref"})
  *Oxobacter pfennigii* DSM 3222                                                           H~2~ + CO~2~, CO                    Acetate, butyrate/no                        36--38                                       7.3                                           CO: 13,9                            LKET01000000              (Krumholz and Bryant, [1985](#mbt213270-bib-0078){ref-type="ref"}; Bengelsdorf *et al*., [2015b](#mbt213270-bib-0010){ref-type="ref"})
  *Sporomusa acidovorans* DSM 3132                                                         H~2~ + CO~2~                        Acetate/yes                                 35                                           6.5--7.0                                                                          LSLL00000000              (Ollivier *et al*., [1985](#mbt213270-bib-0106){ref-type="ref"} Humphreys *et al*., [2017a](#mbt213270-bib-0062){ref-type="ref"})
  *Sporomusa aerivorans* DSM 13326                                                         H~2~ + CO~2~                        Acetate/yes                                 30                                           7.0                                           H~2~ + CO~2:~ 8.9                                             (Boga *et al*., [2003](#mbt213270-bib-0017){ref-type="ref"})
  *Sporomusa malonica* DSM 5090                                                            H~2~ + CO~2~                        Acetate/yes                                 28--32                                       7.3                                                                               FWXI00000000              (Dehning *et al*., [1989](#mbt213270-bib-0033){ref-type="ref"})
  *Sporomusa ovata* DSM 2662                                                               H~2~ + CO~2~                        Acetate/yes                                 34                                           6.3                                                                               ASXP01000008              (Möller *et al*., [1984](#mbt213270-bib-0103){ref-type="ref"} Poehlein *et al*., [2013](#mbt213270-bib-0116){ref-type="ref"})
  *Sporomusa paucivorans* DSM 3697                                                         H~2~ + CO~2~                        Acetate/yes                                 34                                           6.7                                           H~2~ + CO~2:~ 10                                              (Hermann *et al*., [1987](#mbt213270-bib-0057){ref-type="ref"})
  *Sporomusa rhizae* DSM 16652                                                             H~2~ + CO~2~                        Acetate/n.r.                                35                                           7.5                                                                                                         (Gößner, [2006](#mbt213270-bib-0602){ref-type="ref"})
  *Sporomusa silvacetica* DSM 10669                                                        H~2~ + CO~2~                        Acetate/yes                                 25--30                                       5.5--7.7                                                                          LSLK00000000              Kuhner *et al*., [1997](#mbt213270-bib-0079){ref-type="ref"} *;* Humphreys *et al*., [2017b](#mbt213270-bib-0063){ref-type="ref"})
  *Sporomusa sphaeroides* DSM 2875                                                         H~2~ + CO~2~                        Acetate/yes                                 35--37                                       6.5                                                                               LSLJ00000000              (Möller *et al*., [1984](#mbt213270-bib-0103){ref-type="ref"} Castillo *et al*., [2017](#mbt213270-bib-0505){ref-type="ref"})
  *Sporomusa termitida* DSM 4440                                                           H~2~ + CO~2~, CO                    Acetate/yes                                 30                                           7.2                                           H~2~ + CO~2:~ 7.8                                             (Breznak *et al*., [1988](#mbt213270-bib-0021){ref-type="ref"})
  *Terrisporobacter glycolicus* RD‐1[a](#mbt213270-note-0002){ref-type="fn"} DSM 13865     H~2~ + CO~2~                        Acetate/no                                  37--40                                       7.0--7.5                                                                          AUUB01000000              (Küsel *et al*., [2001](#mbt213270-bib-0081){ref-type="ref"}; Gerritsen *et al*., [2014](#mbt213270-bib-0047){ref-type="ref"})
  *Terrisporobacter mayombei* DSM 6539                                                     H~2~ + CO~2~                        Acetate/no                                  33                                           7.3                                           H~2~ + CO~2~: 5                                               (Kane *et al*., [1991](#mbt213270-bib-0067){ref-type="ref"}; Gerritsen *et al*., [2014](#mbt213270-bib-0047){ref-type="ref"})
  *Treponema primitia* DSM 12427                                                           H~2~ + CO~2~                        Acetate/no                                  30                                           7.2                                           H~2~ + CO~2~: 29                    CP001843                  (Graber *et al*., [2004](#mbt213270-bib-0603){ref-type="ref"}; Graber and Breznak, [2004](#mbt213270-bib-0604){ref-type="ref"}; Rosenthal *et al*., [2011](#mbt213270-bib-0611){ref-type="ref"})
  *Calderihabitans maritimus* DSM 26464                                                    CO                                  H~2~ + CO~2~ acetate/no                     65                                           7.0--7.5                                                                          BDGJ00000000              (Yoneda *et al*., [2012](#mbt213270-bib-0615){ref-type="ref"}; Omae *et al*., [2017](#mbt213270-bib-0107){ref-type="ref"})
  *Carboxydothermus ferrireducens* DSM 11255                                               H~2~ + CO~2~, CO                    N.r./no                                     65                                           6.0--6.2                                                                          ATYG00000000              Slobodkin *et al*., [1997](#mbt213270-bib-0609){ref-type="ref"}; Slobodkin, 2006)
  *Carboxydothermus hydrogenoformans* DSM 6008                                             CO                                  H~2~ + CO~2~/no                             70--72                                       6.8--7.0                                      CO: 2                               CP000141                  (Svetlichny *et al*., [1991](#mbt213270-bib-0610){ref-type="ref"}; Wu *et al*., [2005](#mbt213270-bib-0612){ref-type="ref"})
  *Carboxydothermus pertinax* DSM 23698                                                    H~2~ + CO~2~, CO                    H~2~ + CO~2~/no                             65                                           6.0--6.5                                      CO: 1.5                             BDJK00000000              (Yoneda *et al*., [2012](#mbt213270-bib-0615){ref-type="ref"} *;*Fukuyama *et al*., [2017](#mbt213270-bib-0606){ref-type="ref"})
  *Moorella glycerini* [d](#mbt213270-note-0006){ref-type="fn"} DSM 11254                  N.r.                                Acetate/n.r.                                58                                           6.3--6.5                                                                          CELZ00000000              (Slobodkin *et al*., [1997](#mbt213270-bib-0609){ref-type="ref"})
  *Moorella mulderi* DSM 14980                                                             H~2~ + CO~2~                        Acetate/yes                                 65                                           7.0                                                                               LTBC00000000              (Balk *et al*., [2003](#mbt213270-bib-0502){ref-type="ref"}; Castillo *et al*., [2016](#mbt213270-bib-0504){ref-type="ref"})
  *Moorella thermoacetica* DSM 2955                                                        H~2~ + CO~2~, CO                    Acetate/yes                                 55                                           6.9                                           CO: 9‐16                            CP012369                  (Fontaine *et al*., [1942](#mbt213270-bib-0605){ref-type="ref"}; Kerby and Zeikus, [1983](#mbt213270-bib-0607){ref-type="ref"}; Andreesen *et al*., [1973](#mbt213270-bib-0500){ref-type="ref"}; Daniel *et al*., [1990](#mbt213270-bib-0030){ref-type="ref"}; Parekh and Cheryan, [1991](#mbt213270-bib-0608){ref-type="ref"}; Gößner *et al*., [1999](#mbt213270-bib-0601){ref-type="ref"}; Bengelsdorf *et al*., [2015a](#mbt213270-bib-0008){ref-type="ref"}; Poehlein *et al*., [2015a](#mbt213270-bib-0117){ref-type="ref"})
  *Moorella thermoautotrophica* DSM 1974                                                   H~2~ + CO~2~, CO                    Acetate/yes                                 56--60                                       5.7                                           H~2~ + CO~2~: 8                                               (Wiegel *et al*., [1981](#mbt213270-bib-0150){ref-type="ref"})

n.d., not deposited; n.r., not reported.

**a.** No type strain.

**b.** Condition not described as optimal, but used in the reference.

**c.** No validly described species.

**d.** No growth on gas reported, but all Wood--Ljungdahl pathway genes found in the genome.

John Wiley & Sons, Ltd

*Clostridium ljungdahlii* has been isolated for its ability to grow on CO and CO‐containing gas mixtures such as syngas (Tanner *et al*., [1993](#mbt213270-bib-0140){ref-type="ref"}). CO~2~/H~2~ gas mixtures cannot be utilized as efficient as by *A. woodii*. *C. ljungdahlii* also relies on a Rnf complex for generation of an ion gradient, but in this case, it is proton‐dependent (Tremblay *et al*., [2012](#mbt213270-bib-0142){ref-type="ref"}) and thus coupled to a H^+^‐dependent ATPase. The organism is also genetically well accessible and completely sequenced. Recombinant strain construction (butanol) has been achieved as well (Köpke *et al*., [2010](#mbt213270-bib-0074){ref-type="ref"}). *C. ljungdahlii* is meanwhile considered to be a model acetogen for proton bioenergetics and CO utilization.

A very close relative, *C. autoethanogenum*, was described only a few months after *C. ljungdahlii* (Abrini *et al*., [1994](#mbt213270-bib-0001){ref-type="ref"}). Phylogenetically, it contains an identical 16S rRNA gene as *C. ljungdahlii* and both show a very high genome sequence similarity, however, no identity (\> 98%; Humphreys *et al*., [2015](#mbt213270-bib-0061){ref-type="ref"}). Its characteristics are very comparable to *C. ljungdahlii*, with only few differences (Humphreys *et al*., [2015](#mbt213270-bib-0061){ref-type="ref"}). *C. autoethanogenum* was meanwhile developed into the industrial acetogen workhorse, being employed be the leading company in this field, LanzaTech, Inc (Skokie, IL, USA).

Finally, *M. thermoacetica* is a thermophilic acetogen, which was used as model organism for elucidation of the Wood--Ljungdahl pathway. Ironically, this was all performed with sugar‐grown cultures, as CO‐dependent growth was only found much later (Daniel *et al*., [1990](#mbt213270-bib-0030){ref-type="ref"}). Besides being the best characterized acetogenic thermophile, *M. thermoacetica* also uses a different bioenergetic system. The organism possesses an Ech complex (no Rnf) and, in addition, also cytochromes and menaquinone (Gottwald *et al*., [1975](#mbt213270-bib-0050){ref-type="ref"}; Das and Ljungdahl, [2003](#mbt213270-bib-0032){ref-type="ref"}; Pierce *et al*., [2008](#mbt213270-bib-0112){ref-type="ref"}; Schuchmann and Müller, [2014](#mbt213270-bib-0127){ref-type="ref"}). Thus, there are two potential possibilities to generate a proton gradient across the membrane.

Aerobic metabolism of CO, H~2~ and CO~2~ containing gases {#mbt213270-sec-0007}
=========================================================

Whereas anaerobic fermentation of CO, H~2~ and CO~2~‐containing gases with acetogenic bacteria is well known and already employed for industrial ethanol production, the aerobic utilization of such gases for biotechnological purposes is still in its infancy and has not been exploited so far. This certainly is due to the fact that in spite of numerous organisms able to grow chemolithoautotrophically on H~2~, CO~2~ and CO mixtures (King, [2003](#mbt213270-bib-0072){ref-type="ref"}; King and Weber, [2007](#mbt213270-bib-0073){ref-type="ref"}), only few of these so‐called carboxydotrophic bacteria have been characterized in detail, molecular toolboxes for these organisms have not been developed, H~2~ and CO show very low solubility in aqueous solutions, CO is highly toxic, and the handling of H~2~ and CO in the presence of O~2~ requires extensive precautions. However, aerobic CO oxidation is energetically more favourable than anaerobic oxidation and subsequent acetogenesis (reactions 1 and 2, respectively; Diender *et al*., [2015](#mbt213270-bib-0037){ref-type="ref"}) and, thus, aerobic oxidation of CO should allow the production of more costly (i.e. ATP‐intensive) products than CO oxidation via anaerobic acetogenesis.$$\text{Reaction\ I}:2\,\text{CO} + O_{2}\rightarrow 2\,\text{CO}_{2}\qquad\quad{(\Delta G^{0} = - 514\,\text{kJ})}$$ $$\begin{array}{cl}
 & {\text{Reaction\ II}:4\,\text{CO} + 2\text{H}_{2}\,\text{O}\rightarrow\text{CH}_{3}\text{COO}^{-} + \text{H}^{+} + 2\,\text{CO}_{2}} \\
 & {\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad(\Delta\text{G}^{0} = - 174\,\text{kJ})} \\
\end{array}$$

Accordingly, bioreactors for aerobic, carboxydotrophic cultivation need to be equipped with sufficient cooling capacities to buffer the heat release caused by necessarily tightly controlled H~2~ oxidation ($\Delta H_{C}^{0}$ = 286 kJ mole^−1^) which somewhat resembles the cooling demands of comparable sugar‐based, aerobic scenarios.

Species of *Oligotropha, Bradyrhizobium, Mesorhizobium, Hydrogenophaga, Burkholderia* and also some species of *Mycobacterium*,*Pseudomonas, Alcaligenes* and *Acinetobacter* have been reported to grow aerobically on CO and CO‐ and H~2~‐containing gases as sole carbon and energy sources (reviewed in Meyer and Schlegel, [1983](#mbt213270-bib-0098){ref-type="ref"}; King, [2003](#mbt213270-bib-0072){ref-type="ref"}; King and Weber, [2007](#mbt213270-bib-0073){ref-type="ref"}; Weber and King, [2012](#mbt213270-bib-0149){ref-type="ref"}). Especially, carboxydotrophic bacteria such as *Oligotropha carboxidovorans* and *Hydrogenophaga pseudoflava* which possess a highly CO‐tolerant respiratory chain and show high growth rates under autotrophic conditions are promising candidates for future biotechnological application in aerobic gas fermentations (Zavarzin and Nozhevnikova, [1977](#mbt213270-bib-0156){ref-type="ref"}; Cypionka *et al*., [1980](#mbt213270-bib-0029){ref-type="ref"}; Cypionka and Meyer, [1982](#mbt213270-bib-0028){ref-type="ref"}). *Oligotropha carboxidovorans* probably is the best studied carboxydotrophic bacterium. It possesses a CO‐insensitive aerobic electron transport chain, an O~2~‐tolerant molybdenum and copper‐containing CO dehydrogenase for oxidation of CO~2~ and the Calvin--Benson--Bassham cycle for fixation of CO~2~ during autotrophic growth on CO and CO~2~ (Meyer and Schlegel, [1978](#mbt213270-bib-0097){ref-type="ref"}, [1983](#mbt213270-bib-0098){ref-type="ref"}). *O. carboxidovorans* is also able to grow organoheterotrophically with organic acids (Meyer and Schlegel, [1983](#mbt213270-bib-0098){ref-type="ref"}), its genome consists of one chromosome and two megaplasmids, one of which (pHCG3) harbours the (substrate‐inducible) genes required for H~2~ and CO oxidation and for CO~2~ fixation (Fuhrmann *et al*., [2003](#mbt213270-bib-0043){ref-type="ref"}; Paul *et al*., [2008](#mbt213270-bib-0108){ref-type="ref"}; Volland *et al*., [2011](#mbt213270-bib-0148){ref-type="ref"}). However, genetic tools are so far not available for this organism.

Very recently, Heinrich *et al*. ([2017](#mbt213270-bib-0056){ref-type="ref"}) reported on aerobic utilization of syngas by recombinant strains of *Ralstonia eutropha* H16 (currently designated as *Cupriavidus necator* H16). The wild type of this species is an aerobic and chemolithoautotrophic 'Knallgas' bacterium able to efficiently use H~2~ and CO~2~ as sole carbon and energy sources and possessing a hydrogenase and an electron chain which are relatively insensitive towards CO (Cypionka and Meyer, [1982](#mbt213270-bib-0028){ref-type="ref"}; Friedrich and Schwartz, [1993](#mbt213270-bib-0042){ref-type="ref"}; Bürstel *et al*., [2016](#mbt213270-bib-0024){ref-type="ref"}). *C. necator* H16 was genetically engineered to express the genes encoding the *O. carboxidovorans* CO dehydrogenase as well as the genes encoding proteins for maturation of this enzyme. In the presence of H~2~, CO~2~ and CO (plus small amounts of a heterotrophic substrate in the preculture), the resulting strain was able to (slowly) oxidize and use CO as a carbon source, grew slightly faster and produced significantly more poly‐D‐3‐hydroxybutyrate (PHB) than the parental strain carrying the empty plasmid on H~2~ and CO~2~ (Heinrich *et al*., [2017](#mbt213270-bib-0056){ref-type="ref"}). Since *R. eutropha* has been shown to produce several recombinant higher‐value products aside from PHB (reviewed in Dürre and Eikmanns, [2015](#mbt213270-bib-0039){ref-type="ref"}), the metabolic engineering strategy applied seems very promising for further biotechnological exploitation.

The development of genetic tools for aerobic, carboxydotrophic bacteria is still in the beginning. However, genome analysis of promising representatives, establishment of sophisticated genetic engineering tools such as efficient transformation, differential expression of homologous and heterologous genes, markerless deletions and/or allelic exchanges should allow the construction of one or more carboxydotrophic (platform or model) organism/s for future biotechnological applications, that is for aerobic utilization of syngas for the production of value‐added products.

Bioprocess developments {#mbt213270-sec-0008}
=======================

Autotrophic growth of acetogens is extremely energy limited and gas--liquid mass transport limitations restrict biocatalytic activities due to the low solubilities of the gaseous substrates H~2~ and CO in water at ambient pressure. H~2~ is 65 mol% and CO is 75 mol% less soluble in water compared to O~2~ (1 bar, 20 °C). Compared to typical aerobic heterotrophic bioprocesses, planktonic cell concentrations are reduced by a factor of 10 and more, resulting in low volumetric productivities of gas fermentations.

Gas--liquid mass transfer can be improved by increasing the volumetric power input into bioreactors with dispersed gas phase (e.g. increasing the stirrer speed in stirred‐tank bioreactors) and/or increasing the partial pressures of H~2~ and CO in the gas phase. Increasing the power input per unit volume will cause severe scale‐up challenges and will be economically demanding if low value adding products are produced from syngas like C2‐C4 alcohols or acids. Increasing the partial pressures of H~2~ and CO will thus be the method of choice, for example by applying bioreactors with liquid heights *h* of 20--30 m to build up a high hydrostatic pressure at the bottom of the reactor where the syngas is dispersed. Amongst others, these are the reasons why bubble‐column or gas‐lift reactors are chosen for syngas fermentations with planktonic cells on an industrial scale. It must be pointed out that increased partial pressures of the gaseous substrates are favourable from a thermodynamic point of view as well.

The power input of bubble‐column reactors on an industrial scale is caused by the isothermal expansion of the gas phase dispersed at the bottom of the reactor (*P* ~Exp~)$$P_{Exp} = \frac{{\overset{˙}{V}}_{gas} \cdot \rho_{gas}}{{\overset{\sim}{M}}_{gas}} \cdot \text{RT} \cdot \text{In}\left( \frac{1 + \rho_{L} \cdot g \cdot h}{p_{U}} \right),$$with ${\overset{˙}{V}}_{gas}$ as the inlet gas flow rate, *ρ* ~gas~ as the density of the gas, ${\overset{\sim}{M}}_{gas}$ as the molecular weight of the gas, *p* ~*U*~ as the pressure above the liquid surface (head‐space pressure), *ρ* ~L~ as the density of the liquid phase, *g* as the acceleration of gravity and *h* as the liquid height above the gas sparger in the reactor. The power input *P* ~Exp~ increases with raising gas inlet flow rate and liquid height *h*. Due to the elevated partial pressures of the gases in the inlet at high liquid heights, increasing the liquid height *h* results in elevated partial pressures at the bottom of the bubble‐column reactor and increased power input both serving for improved gas--liquid mass transfer. As a consequence, solely acetogenic producer strains can be applied for syngas fermentation which are not inhibited by increased H~2~‐ or CO‐partial pressures of up to a few bar. Unfortunately, H~2~‐ or CO‐inhibition kinetics of acetogens are not very well studied so far (e.g. Vega *et al*., [1988](#mbt213270-bib-0145){ref-type="ref"}; Chang *et al*., [1998](#mbt213270-bib-0025){ref-type="ref"}; Skidmore *et al*., [2013](#mbt213270-bib-0133){ref-type="ref"}; Mohammadi *et al*., [2014](#mbt213270-bib-0101){ref-type="ref"}).

The partial pressures in the gas bubbles rising in a bubble column vary considerably as function of the height *h* in the column due to the consumption and production of gases by acetogens in the liquid phase and due to the decline of the total pressure. As a consequence, axial gradients are inevitable with respect to the partial pressures of the gas phase as well as the concentrations of biomass, products and pH in the liquid phase along the height of the bubble‐column reactor. Whereas the multiphase transport processes can be described by well‐known modelling approaches (e.g. plug flow of both phases with axial dispersion and gas--liquid mass transport in bubble columns), the gas consumption and product formation kinetics of acetogens as function of substrate (H~2~, CO) and product concentrations (acetate, ethanol, etc.) as well as pH are not very well known. An approach to overcome this lack of kinetic information is making use of a genome‐scale metabolic reconstruction of acetogens combined with uptake kinetics for H~2~ and CO (e.g. Chen *et al*., [2015](#mbt213270-bib-0027){ref-type="ref"}).

Further studies on the kinetics of acetogens in fully controlled and well‐mixed laboratory‐scale stirred‐tank bioreactors are inevitable to provide the kinetic data which are needed for the modelling of syngas fermentation in bubble columns on an industrial scale. Batch syngas fermentation processes in stirred‐tank bioreactors will provide basic performance data (e.g. Demler and Weuster‐Botz, [2011](#mbt213270-bib-0035){ref-type="ref"}, Groher and Weuster‐Botz, [2016a](#mbt213270-bib-0053){ref-type="ref"},[b](#mbt213270-bib-0054){ref-type="ref"}; Kantzow and Weuster‐Botz, [2016](#mbt213270-bib-0069){ref-type="ref"}; Mayer and Weuster‐Botz, [2017](#mbt213270-bib-0094){ref-type="ref"}) but continuous syngas fermentations should be preferred due to the possibility to perform steady‐state studies (e.g. Mohammadi *et al*., [2012](#mbt213270-bib-0100){ref-type="ref"}). Low growth rates of acetogens especially if extreme reaction conditions are to be studied may be an obstacle (e.g. pH, T, inhibiting gas concentrations). The application of submerged microfiltration membranes in a continuously operated stirred‐tank bioreactor enables the study of syngas fermentations with (total) cell retention (Kantzow *et al*., [2015](#mbt213270-bib-0070){ref-type="ref"}). A cascade of stirred‐tank bioreactors is another option with the first reactor operated at optimum autotrophic growth conditions for acetogens and the second reactor at extreme reaction conditions, for example for studying the reconsumption of acids and the production of alcohols at low pH without growth (Richter *et al*., [2013](#mbt213270-bib-0121){ref-type="ref"}; Martin *et al*., [2015](#mbt213270-bib-0093){ref-type="ref"}).

One of the first commercial plants for the conversion of CO‐rich industrial off‐gases of a steel mill is presently under construction at the ArcelorMittal steel mill in Ghent (Belgium) making use of continuously operated bubble‐column/gas‐lift loop reactors. The syngas fermentation process developed by LanzaTech uses *Clostridium autoethanogenum* for the production of ethanol with an estimated volumetric productivity of around 10 g l^−1^ h^−1^. The syngas fermentation plant in Ghent is designed for an annual production capacity of 60.000 m^3^ ethanol converting 50.000 Nm^3^ h^−1^ steel mill off‐gases (Molitor *et al*., [2016](#mbt213270-bib-0102){ref-type="ref"}) and is due to be operational in 2019. CO utilization of around 70--75% was shown at the Shougang (China) demonstration facility of LanzaTech (Heijstra *et al*., [2017](#mbt213270-bib-0055){ref-type="ref"}). Current approaches even strive for almost complete CO utilization.

A promising alternative to bubble columns or gas‐lift reactors may be trickle‐bed biofilm reactors. A biofilm is formed on the (inner) surfaces of carrier materials forming a fixed‐bed in a cylindrical reactor. The liquid phase is distributed above the fixed‐bed and trickles down forming a thin liquid film on the surface of the carriers. In contrast to bubble‐column reactors, the gas phase is not dispersed in the liquid phase but forms the continuous phase in the trickle‐bed reactor. The pressure drop of the gas phase is thus negligible, and the power input of trickle‐bed reactors is solely caused by pumping the liquid phase to the top of the fixed‐bed of the trickle‐bed reactor. Despite the low power input, the gas--liquid and gas‐biofilm mass transfer becomes high at low liquid film thickness, high flow rates of the trickling liquid and low biofilm thickness. Due to the low operating costs at high mass transfer rates, trickle‐bed biofilm reactors and a special design of thereof, so‐called horizontal rotating packed‐bed biofilm reactors, are widespreadly used in waste water treatment plants.

Very few studies have been reported so far on the application of trickle‐bed reactors for syngas fermentation on a laboratory‐scale (e.g. Bredwell *et al*., [1999](#mbt213270-bib-0020){ref-type="ref"}; Yasin *et al*., [2015](#mbt213270-bib-0154){ref-type="ref"}; Devarapalli *et al*., [2016](#mbt213270-bib-0036){ref-type="ref"}; Schulte *et al*., [2016](#mbt213270-bib-0128){ref-type="ref"}; Shen *et al*., [2017](#mbt213270-bib-0130){ref-type="ref"}). High CO conversion rates of up to 91% were observed with *Clostridium ragsdalei* in a trickle‐bed reactor with non‐porous glass beads of 6 mm as carriers (Devarapalli *et al*., [2016](#mbt213270-bib-0036){ref-type="ref"}). H~2~ utilization of more than 80% was measured in a laboratory‐scale horizontal rotating packed‐bed biofilm reactor with *Clostridium carboxidivorans* P7 with non‐porous HDPE carriers with a specific surface area of 500 m^2^ m^‐3^. Compared to the syngas fermentation with a continuous operated stirred‐tank bioreactor at the same operation conditions, the volumetric ethanol productivity was 3.3 times higher (Shen *et al*., [2017](#mbt213270-bib-0130){ref-type="ref"}). Biofilm formation seems to be not an issue with acetogens although systematic studies are missing so far.

Axial gradients of pH and product concentrations are inevitable in the trickling liquid phase along the height of a trickle‐bed reactor on an industrial scale (10 ‐ 15 m). Recycling of the liquid phase may be a solution to reduce gradients but will increase the volumetric power input. Compared to bubble‐column or gas‐lift reactors, the liquid phase and biomass volume ('working volume') are very much reduced in trickle‐bed reactors to about 20% of the total volume compared to about 80% in bubble‐column reactors. The reduced working volume of trickle‐bed biofilm reactors will be balanced by improved mass transfer which is shown by higher volumetric productivities. However, industrial application of trickle‐bed biofilm reactors for syngas fermentation will only be possible if a stable biofilm can be established for long‐term operation, especially if recombinant acetogens will be applied for the (improved) production of natural or non‐natural products. Unfortunately, no studies on control, stability and long‐term operation of biofilms with (recombinant) acetogens have been published so far.

Downstream processing {#mbt213270-sec-0009}
=====================

'Molecules don\'t jump out of the broth'. The old wisdom is still valid, for commodities as well as for performance molecules. Given that 30--50% of manufacturing costs of commodities are typically assigned to downstream processing (DSP), processes may gain or lose their economic viability in the downstream section. In general, DSP aims at providing products that meet given purity specifications. However, specification sheets of VAC intermediates and other commoditized molecules are mainly derived from fossil‐based production. Accordingly, listed impurities mirror the needs when dealing with fossil raw materials and do not cover impurity patterns of bioprocesses. A basic change of mindset is necessary, because fossil‐based impurities enter processes as co‐substrates while bioprocesses typically produce non‐wanted impurities via metabolic reactions. In consequence, specifications need to be revisited to fulfil their purpose of guaranteeing the performance of the respective product within the VAC and for the application. By‐products of fermentation need to be integrated in 'conventional' specification lists checking whether or not their occurrence hampers the efficiency of subsequent processing steps or even the functionality of the final product. For instance, low impurity concentrations may cause non‐wanted caking in DSP which in turn may necessitate repeated strain engineering to prevent by‐product formation. The example outlines the crucial importance of mass balancing in DSP to track impurities. Furthermore, it shows that total bioprocess development is a workflow of different activities with distinct interfaces and feedback loops that needs to be cycled several times to succeed (Fig. [3](#mbt213270-fig-0003){ref-type="fig"}).

![Bioprocess development to replace intermediates of an existing VAC by bioproducts. The need to fulfil given specifications but also to check for distinct bio‐originated new ones is outlined by the feed forward and backward loops.](MBT2-11-606-g003){#mbt213270-fig-0003}

Intrinsic benefits of gas fermentation evaluated by conceptual design {#mbt213270-sec-0010}
=====================================================================

As outlined above, the minimization of manufacturing costs is key for the production of VAC intermediates and commodities. Accordingly, criteria shown in Figure [1](#mbt213270-fig-0001){ref-type="fig"} need to be optimized. Some helpful evaluation may even be performed during early‐stage conceptual design using rather simple but characteristic assumptions. Considering a common sugar‐based production capacity of 100 kilo‐tons per annum (kta), average space--time yield (STY) of 4 g l^−1^ h^−1^, product titre of 100 g^−^l^−1^ (achieved after 40 h batch‐time including turnaround), total product recovery of 85% and operation time of 8000 h a^−1^, the following conclusion can be drawn: 200 batch cycles per annum will be necessary, cycling about 5882 m³ batch^−1^. Consequently, 12 bioreactors, each ≥ 500 m³ working volume will be needed. However, gas fermentations offer the advantage to run in continuous mode which will extend 'batch‐times' to 100 h. As a result, only 6 bioreactors≥ 500 m³ working volume will be needed which illustrates the economic potential to save CAPEX (capital expenditure) and OPEX (operational expenditure) with gas fermentations. To improve the latter, gas fermentations typically consider operational pressures up to 4 bar for ensuring sufficient mass transfer and reasonable specific power input \<0.3 kW m^−^³ in combination with loops to consume the gaseous substrates as good as possible.

Size matters -- large‐scale production of intermediates {#mbt213270-sec-0011}
=======================================================

Based on decades of experience within chemical process engineering, routines and short cut methods exist to predict large‐scale capital and operational expenditures. Such algorithms typically predict specific CAPEX decrease with increasing capacity because costs of apparatuses nonlinearly increase with size. Beyond maximum apparatus size, numbering‐up of equal devices is applied which keeps specific CAPEX constant. Such limits strongly depend on the devices used. For instance, solid‐/liquid separation equipment such as centrifuges reaches the limit of scale‐up much earlier than liquid processing equipment such as distillation columns.

The principle also holds true for different types of reactors. Continuous chemical reactor systems usually reach their maximum economy of scale at significantly higher capacities than batch‐type bioreactors. Of course, this depends on process‐specific performance indicators, that is space--time yield and catalyst‐specific productivity. Accordingly, a fossil‐based process to produce a commodity such as acrylic acid might reach its maximum economy of scale at capacities \> 200 kt a^−1^. In comparison, the fermentative production analogue of the respective precursor will get at the said limit already \< 100 kt a^−1^. In other words, bioprocesses accomplish economy of scale with less product than chemical counterparts.

The relation between CAPEX of a specific intermediate and the capacity of a respective bio‐based process and production plant significantly depends on the 'nature' of the product and in consequence the efforts to be taken to deplete impurities. The lowest cost might be achieved with a low‐boiling product that can be purified by distillation of the aqueous reaction mixture, for example ethanol. Also, gaseous products are advantageous in terms of DSP in case those could be purified via fractional condensation or pressure swing adsorption. Products which need to be handled as crystals demand higher specific CAPEX since solid‐/liquid separation and solids processing apparatus come at higher specific cost.

The perspective {#mbt213270-sec-0012}
===============

As already outlined, gas fermentations using mixtures of CO, CO~2~ and H~2~ possess the inherent potential to substitute fossil‐derived components by bio‐based intermediates thereby continuing with already established VACs. CAPEX and OPEX scenarios look promising for production capacities \> 100 kt a^−1^ provided that product specifications are met. The successful solution of this challenge asks for improvements in strain and process engineering. Intrinsic problems of mass transfer and bioreactor design need to be solved which demands for the application of novel knowledge‐based scale‐up approach as already outlined in Takors ([2012](#mbt213270-bib-0138){ref-type="ref"}) and Delvigne *et al*. ([2017](#mbt213270-bib-0034){ref-type="ref"}). Besides, the economic access to electron‐donating substrates (CO, H~2~) is a prerequisite of every industrial process. Individual solutions may be found in highly networked composite chemical sites or via integration in future international energy grids.

CO~2~, CO and H~2~ were in the focus of this review, but alternatives such as CH~4~ may be promising as well. The latter offers access to ATP‐demanding product biosynthesis under aerobic conditions, thereby bypassing the intrinsic ATP limitations of anaerobic CO~2~, CO and H~2~ metabolism. However, aerobic carboxydotrophic strains may be another alternative requiring intensified research and sensitive large‐scale engineering in compliance with ATEX regulations (ATmosphères EXplosibles).

Currently, companies such as LanzaTech are succeeding to implement industrial scale gas fermentation for the production of native products such as ethanol or 2,3‐butanediol. However, the turnaround from fossil raw materials to zero‐CO~2~ emission requires for much more VAC intermediates, as outlined above. The time is right to start research.
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